公开(公告)号：US20200071325A1

公开(公告)日：2020-03-05

申请号：US16559138

申请日：2019-09-03

Applicant: THERAVANCE BIOPHARMA R&D IP, LLC

Inventor： Daniel D. Long ,  Cameron Smith ,  Corbin Thompson

IPC: C07D471/04 ,  C07D519/00 ,  A61P11/06 ,  A61K9/00

Abstract: The invention provides compounds of formula (I): where the variables are defined in the specification, or a pharmaceutically-acceptable salt thereof, that are useful as JAK kinase inhibitors. The invention also provides pharmaceutical compositions comprising such compounds and methods of using such compounds to treat respiratory diseases.

公开(公告)号：US10519153B2

公开(公告)日：2019-12-31

申请号：US16225473

申请日：2018-12-19

Applicant: THERAVANCE BIOPHARMA R&D IP, LLC

Inventor： Paul R. Fatheree ,  Gary E. L. Brandt ,  Cameron Smith ,  Steven D. E. Sullivan ,  Lori Jean Van Orden ,  Melanie A. Kleinschek ,  Glenn D. Crater

IPC: C07D471/04 ,  C07D519/00 ,  A61P11/06 ,  A61P11/00

Abstract: The invention provides compounds of formula (I): where the variables are defined in the specification, or a pharmaceutically-acceptable salt thereof, that are useful as JAK kinase inhibitors. The invention also provides pharmaceutical compositions comprising such compounds, methods of using such compounds to treat respiratory diseases, and processes and intermediates useful for preparing such compounds.

公开(公告)号：US20190337945A1

公开(公告)日：2019-11-07

申请号：US16511410

申请日：2019-07-15

Applicant: THERAVANCE BIOPHARMA R&D IP, LLC

Inventor： Paul R. FATHEREE ,  Gary E.L. Brandt ,  Cameron Smith ,  Steven D.E. Sullivan ,  Lori Jean Van Orden ,  Melanie A. Kleinschek ,  Glenn D. Crater

IPC: C07D471/04 ,  A61P11/06 ,  A61P11/00 ,  C07D519/00

Abstract: The invention provides compounds of formula (I): which contain a 4-membered heterocyclic amide, where the variables are defined in the specification, or a pharmaceutically-acceptable salt thereof, that are useful as JAK kinase inhibitors. The invention also provides pharmaceutical compositions comprising such compounds, methods of using such compounds to treat respiratory diseases, and processes and intermediates useful for preparing such compounds.

公开(公告)号：US20190106420A1

公开(公告)日：2019-04-11

申请号：US16215194

申请日：2018-12-10

Applicant: THERAVANCE BIOPHARMA R&D IP, LLC

Inventor： Paul R. Fatheree ,  John R. Jacobsen ,  Gary E.L. Brandt ,  Melissa Fleury ,  Lan Jiang ,  Cameron Smith ,  Steven D.E. Sullivan ,  Lori Jean Van Orden ,  Anne-Marie Beausoleil

IPC: C07D471/04

CPC classification number: C07D471/04

Abstract: The invention provides compounds of formula (I): wherein X is and the variables are defined in the specification, or a pharmaceutically-acceptable salt thereof, that are useful as JAK kinase inhibitors. The invention also provides pharmaceutical compositions comprising such compounds, methods of using such compounds to treat respiratory diseases, and processes and intermediates useful for preparing such compounds.

公开(公告)号：US20180051023A1

公开(公告)日：2018-02-22

申请号：US15638733

申请日：2017-06-30

Applicant: THERAVANCE BIOPHARMA R&D IP, LLC

Inventor： Melissa Fleury ,  Roland Gendron ,  Adam D. Hughes ,  Cameron Smith

IPC: C07D471/04 ,  C07D487/04 ,  A61K31/415 ,  A61K31/4192 ,  A61K31/4196 ,  A61K31/42 ,  A61K31/437 ,  A61K31/505 ,  A61K45/06 ,  C07C243/28 ,  C07C271/22 ,  C07D231/14 ,  C07D231/20 ,  C07D239/34 ,  C07D239/36 ,  C07D249/04 ,  C07D249/10 ,  C07D249/18 ,  C07D257/04 ,  C07D261/12 ,  C07D261/18 ,  C07D403/04

CPC classification number: C07D471/04 ,  A61K31/415 ,  A61K31/4192 ,  A61K31/4196 ,  A61K31/42 ,  A61K31/437 ,  A61K31/505 ,  A61K45/06 ,  C07C243/28 ,  C07C271/22 ,  C07C2601/02 ,  C07D231/14 ,  C07D231/20 ,  C07D239/34 ,  C07D239/36 ,  C07D249/04 ,  C07D249/10 ,  C07D249/18 ,  C07D257/04 ,  C07D261/12 ,  C07D261/18 ,  C07D403/04 ,  C07D487/04

Abstract: In one aspect, the invention relates to compounds having the formula: where R1, R2a, R2b, R3-R6, a, b, Z, and X are as defined in the specification, or a pharmaceutically acceptable salt thereof. These compounds have neprilysin inhibition activity. In another aspect, the invention relates to pharmaceutical compositions comprising such compounds; methods of using such compounds; and processes and intermediates for preparing such compounds.

公开(公告)号：US20220306624A1

公开(公告)日：2022-09-29

申请号：US17688001

申请日：2022-03-07

Applicant: THERAVANCE BIOPHARMA R&D IP, LLC

Inventor： Paul R. Fatheree ,  John R. Jacobsen ,  Anne-Marie Beausoleil ,  Gary E.L. Brandt ,  Melissa Fleury ,  Lan Jiang ,  Cameron Smith ,  Steven D.E. Sullivan ,  Lori Jean Van Orden ,  Pierre-Jean Colson ,  Gene Timothy Fass ,  Miroslav Rapta ,  Noah Benjamin ,  Marta Dabros ,  Venkat R. Thalladi

IPC: C07D471/04 ,  A61K31/437 ,  A61K31/416 ,  A61P43/00 ,  A61P11/06 ,  A61P11/00

Abstract: The invention provides compounds of formula (I): wherein X is and the variables are defined in the specification, or a pharmaceutically-acceptable salt thereof, that are useful as JAK kinase inhibitors. The invention also provides pharmaceutical compositions comprising such compounds, methods of using such compounds to treat respiratory diseases, and processes and intermediates useful for preparing such compounds.

公开(公告)号：US11254669B2

公开(公告)日：2022-02-22

申请号：US16679676

申请日：2019-11-11

Applicant: THERAVANCE BIOPHARMA R&D IP, LLC

Inventor： Paul R. Fatheree ,  Gary E. L. Brandt ,  Cameron Smith ,  Steven D. E. Sullivan ,  Lori Jean Van Orden

IPC: C07D471/04 ,  C07D519/00 ,  A61P11/06 ,  A61P11/00

Abstract: The invention provides compounds of formula (I): where the variables are defined in the specification, or a pharmaceutically-acceptable salt thereof, that are useful as JAK kinase inhibitors. The invention also provides pharmaceutical compositions comprising such compounds, methods of using such compounds to treat respiratory diseases, and processes and intermediates useful for preparing such compounds.

公开(公告)号：US20210155620A1

公开(公告)日：2021-05-27

申请号：US17248717

申请日：2021-02-04

Applicant: THERAVANCE BIOPHARMA R&D IP, LLC

Inventor： Daniel D. Long ,  Cameron Smith ,  Corbin Thompson

IPC: C07D471/04

Abstract: The invention provides compounds of formula (I): where the variables are defined in the specification, or a pharmaceutically-acceptable salt thereof, that are useful as JAK kinase inhibitors. The invention also provides pharmaceutical compositions comprising such compounds and methods of using such compounds to treat respiratory diseases.

公开(公告)号：US10954237B2

公开(公告)日：2021-03-23

申请号：US16701426

申请日：2019-12-03

Applicant: THERAVANCE BIOPHARMA R&D IP, LLC

Inventor： Paul R. Fatheree ,  Gary E. L. Brandt ,  Cameron Smith ,  Steven D. E. Sullivan ,  Lori Jean Van Orden

IPC: C07D471/04 ,  C07D519/00 ,  A61P11/06 ,  A61P11/00

Abstract: The invention provides compounds of formula (I): which contain a 4-membered heterocyclic amide, where the variables are defined in the specification, or a pharmaceutically-acceptable salt thereof, that are useful as JAK kinase inhibitors. The invention also provides pharmaceutical compositions comprising such compounds, methods of using such compounds to treat respiratory diseases, and processes and intermediates useful for preparing such compounds.

公开(公告)号：US20210024517A1

公开(公告)日：2021-01-28

申请号：US16949067

申请日：2020-10-13

Applicant: THERAVANCE BIOPHARMA R&D IP, LLC

Inventor： Daniel D. Long ,  Cameron Smith ,  Corbin Thompson

IPC: C07D471/04 ,  A61K9/00 ,  A61P11/06 ,  C07D519/00

Abstract: The invention provides compounds of formula (I): where the variables are defined in the specification, or a pharmaceutically-acceptable salt thereof, that are useful as JAK kinase inhibitors. The invention also provides pharmaceutical compositions comprising such compounds and methods of using such compounds to treat respiratory diseases.